{
    "data": [
        {
            "id": "994971",
            "type": "article",
            "attributes": {
                "publishOn": "2012-11-09T11:51:46-05:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Obamacare Just Part Of The Mylan Story",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24276",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/994971-obamacare-just-part-of-the-mylan-story"
            }
        },
        {
            "id": "991831",
            "type": "article",
            "attributes": {
                "publishOn": "2012-11-08T15:46:38-05:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Mylan: Profit From The Generics Boom With This Pharma",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "29161",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "108076",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/991831-mylan-profit-from-the-generics-boom-with-this-pharma"
            }
        },
        {
            "id": "840501",
            "type": "article",
            "attributes": {
                "publishOn": "2012-08-31T12:23:29-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Generics Will Drive Mylan Higher By 2013",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "29161",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/840501-generics-will-drive-mylan-higher-by-2013"
            }
        },
        {
            "id": "634951",
            "type": "article",
            "attributes": {
                "publishOn": "2012-06-04T09:36:39-04:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Mylan: Going Defensive With This Generic Drug Maker",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23762",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "102094",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/634951-mylan-going-defensive-with-this-generic-drug-maker"
            }
        },
        {
            "id": "607311",
            "type": "article",
            "attributes": {
                "publishOn": "2012-05-22T03:06:45-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Mylan: Execution, Valuation Discount Suggest Further Upside Ahead",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20725",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "101600",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/607311-mylan-execution-valuation-discount-suggest-further-upside-ahead"
            }
        },
        {
            "id": "541061",
            "type": "article",
            "attributes": {
                "publishOn": "2012-04-30T03:27:45-04:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Mylan Worth $24, Upside Greater At Teva, Pfizer",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24866",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "100557",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/541061-mylan-worth-24-upside-greater-at-teva-pfizer"
            }
        },
        {
            "id": "382871",
            "type": "article",
            "attributes": {
                "publishOn": "2012-02-22T09:39:06-05:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Mylan Looks To Reap A Harvest Of Patent Expirations",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24361",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/382871-mylan-looks-to-reap-a-harvest-of-patent-expirations"
            }
        },
        {
            "id": "329552",
            "type": "article",
            "attributes": {
                "publishOn": "2012-01-31T15:45:47-05:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Mylan's Staggering Upside Dwarfs J&J, Endo",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24866",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "97279",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/329552-mylans-staggering-upside-dwarfs-j-and-j-endo"
            }
        },
        {
            "id": "321660",
            "type": "article",
            "attributes": {
                "publishOn": "2012-01-24T12:59:14-05:00",
                "isLockedPro": false,
                "commentCount": 8,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why I Am Adding Mylan To My Portfolio",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23762",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/321660-why-i-am-adding-mylan-to-my-portfolio"
            }
        }
    ]
}